

WASHINGTON, DC – Congressman Lee Terry (R-NE) voted in favor of the Food and Drug Administration Reform Act (H.R. 5651), which passed the House by a vote of 387 to 5.

"The FDA reform bill contains common-sense legislation that ensures patients receive quality care and timely access to new therapies, while promoting innovation and job creation," Terry said. "By reauthorizing user fee programs and enacting new ones, the FDA has the opportunity to accelerate the review process and make more-timely decisions on prescription and generic drugs, biosimilars, and medical devices. American patients will be the beneficiaries of these innovative and cutting-edge technologies."

The FDA Reform Act extends the FDA's current user fee programs, which are set to expire in September, for an additional five years. These programs, the Prescription Drug User Fee Act and the Medical Device User Fee Act, are essential to ensure groundbreaking medicines and technologies reach the patients who need them the most. The bipartisan reform bill also supports new user fee programs for generic drugs and biosimilars, thereby, allowing a greater range of affordable healthcare options to hit the market and made available to more patients.

Other provisions contained in the FDA reform bill would mitigate the drug shortage issue, create incentives for the development of antibiotics and reauthorize language that encourages the testing and production of children's pharmaceuticals.